Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome–positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

By  

CANCER, Vol. 122, Iss. 19, 2016-10 ,pp. : 2941-2951

John Wiley & Sons Inc

Access to resources Recommend Favorite

BCR/ABL1 Kinase Domain Mutation Monitoring: Could Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Benefit As Well?

By  

Acta Haematologica, Vol. 134, Iss. 2, 2015-04 ,pp. : 69-70

Karger

Access to resources Recommend Favorite

Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement

By  

CANCER, Vol. 120, Iss. 7, 2014-04 ,pp. : 1002-1009

John Wiley & Sons Inc

Access to resources Recommend Favorite

Second-Generation Tyrosine Kinase Inhibitors in the Post-Transplant Period in Patients with Chronic Myeloid Leukemia or Philadelphia-Positive Acute Lymphoblastic Leukemia

By  

Acta Haematologica, Vol. 122, Iss. 1, 2009-07 ,pp. : 6-10

Karger

Access to resources Recommend Favorite

Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: Current Status and Challenges

By  

Acta Haematologica, Vol. 112, Iss. 1-2, 2004-06 ,pp. : 34-39

Karger

Access to resources Recommend Favorite